SCHEMBL2452818

SCHEMBL2452818

Cc1nc(Cl)c(-c2c(F)cc(F)cc2F)n1-c1cnc2ccccc2c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 4/20 0.41
PIK3CD O00329 2/20 0.41
MTOR P42345 2/20 0.41
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
HTR3A P46098 1/20 0.40
CYP1A2 P05177 1/20 0.39
NPC1 O15118 2/20 0.37
MAPT P10636 2/20 0.37
RAB9A P51151 2/20 0.37
GLA P06280 1/20 0.36
DHFR P00374 1/20 0.36
CNR1 P21554 3/20 0.35
CNR2 P34972 3/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNA4 P43681 1/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2449304 0.89 CYP11B1 (0.38) PIK3CAPIK3CDMTORCYP11B1CYP11B2
SCHEMBL2450914 0.88 CYP11B1 (0.39) PIK3CAPIK3CDMTORCYP11B1CYP11B2
SCHEMBL2451435 0.81 PIK3CA (0.34) PIK3CAPIK3CDMTORGLA
SCHEMBL2451254 0.81 GRM5 (0.35) PIK3CAMTORCYP11B2GLA
SCHEMBL1074563 0.79 NOTUM (0.37) CYP1A2GLAALDH1A1KDM4E
SCHEMBL1074623 0.78 PIK3CA (0.41) PIK3CAMAPTKDM4E
SCHEMBL2451300 0.78 HTR3A (0.38) PIK3CACYP11B1CYP11B2HTR3ACYP1A2
SCHEMBL2450913 0.78 ALDH1A1 (0.38) HTR3ACYP1A2NPC1MAPTRAB9A
SCHEMBL2452981 0.78 OXTR (0.46)
SCHEMBL1074256 0.76 GRM1 (0.43) CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110311649-A1 NOVEL IMIDAZOLE DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2011-12-22 US claimed
EP-2201001-B1 NOVEL IMIDAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2011-09-14 EP claimed
EP-2201001-A1 NOVEL IMIDAZOLE DERIVATIVES Syngenta Participations AG (CH) 2010-06-30 EP claimed
WO-2009053101-A1 NOVEL IMIDAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2009-04-30 WO claimed
EP-2053044-A1 Novel imidazole derivatives Syngenta Participations AG (CH) 2009-04-29 EP claimed
EP-2053046-A1 Novel imidazole derivatives Syngeta Participations AG (CH) 2009-04-29 EP claimed
US-20110311649-A1 NOVEL IMIDAZOLE DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2011-12-22 US disclosed
EP-2201001-B1 NOVEL IMIDAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2011-09-14 EP disclosed
EP-2201001-A1 NOVEL IMIDAZOLE DERIVATIVES Syngenta Participations AG (CH) 2010-06-30 EP disclosed
WO-2009053101-A1 NOVEL IMIDAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2009-04-30 WO disclosed
EP-2053044-A1 Novel imidazole derivatives Syngenta Participations AG (CH) 2009-04-29 EP disclosed
EP-2053046-A1 Novel imidazole derivatives Syngeta Participations AG (CH) 2009-04-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110311649-A1 NOVEL IMIDAZOLE DERIVATIVES CBR3, C3AR1, C1R PIK3CA 2874/4885PIK3CD 1778/4885MTOR 2145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.